Preclinical News and Research

RSS

Surefire Medical’s latest line of infusion system and specialty catheters receive CE Mark approval

Surefire Medical, Inc., the developer of a new class of infusion systems designed to maximize targeted delivery of embolization agents without reflux, today announced CE Mark approval for its Surefire Infusion System ST/LT and Surefire Specialty Catheters.

26 Feb 2013

Sius single-use tangential flow filtration skid from Novasep

Novasep, a leading supplier of manufacturing solutions to the life sciences industries, today announces the launch of its Sius single-use tangential flow filtration (TFF) skid.

26 Feb 2013

Recombinant Newcastle disease virus kills all kinds of prostate cancer cells

A recombinant Newcastle disease virus kills all kinds of prostate cancer cells, including hormone resistant cells, but leaves normal cells unscathed, according to a paper published online ahead of print in the Journal of Virology.

26 Feb 2013

Adynxx initiates AYX1 Phase 2 study to prevent post-surgical pain

Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in a Phase 2 study of its lead investigational drug candidate for the prevention of post-surgical pain, AYX1.

26 Feb 2013

Okairos to commence novel RSV vaccine Phase I clinical trial

Okairos today announced the initiation of a Phase I clinical trial evaluating a vaccine against respiratory syncytial virus (RSV), a leading cause of hospital admissions in infants and children.

25 Feb 2013

Orphan, CU to develop enzyme replacement therapy for CBS-deficient homocystinuria

The University of Colorado (CU) has signed exclusive, worldwide licensing and collaboration agreements with rare-disease research-and-development firm Orphan Technologies Ltd to develop an enzyme replacement therapy for Cystathionine Beta-Synthase (CBS) -deficient homocystinuria, a rare, inherited metabolic disease that is often fatal at a young age.

25 Feb 2013

Researchers determine that neuroblastoma is sensitive to BET bromodomain inhibitors

Neuroblastoma, the most common malignant tumor of early childhood, is frequently associated with the presence of MYCN amplification, a genetic biomarker associated with poor prognosis. Researchers have determined that tumors containing MYCN amplification are sensitive to a new class of drugs, BET bromodomain inhibitors.

22 Feb 2013

New mouse model can advance research on iPS cells to next step

VIB scientists associated to the UGent have developed a mouse model that can advance the research on iPS cells to the next step.

21 Feb 2013

Two new non-invasive technologies can improve early identification of tumor response to therapy

The research was published early in the January issue of the journal Technology in Cancer Research and Treatment. The article describes experiments using ultrasonic molecular imaging (USMI) and Dynamic Contrast Enhanced-Perfusion Imaging (DCE-PI) to measure response to therapy for pancreatic cancer.

21 Feb 2013

GCP could help lengthen life expectancy of certain prostate cancer patients

A natural, nontoxic product called genistein-combined polysaccharide, or GCP, which is commercially available in health stores, could help lengthen the life expectancy of certain prostate cancer patients, UC Davis researchers have found.

21 Feb 2013

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation announced today that Immune is initiating, following authorization from Israeli health authorities, a Phase II double-blind placebo controlled study with its lead drug, bertilimumab, in patients with moderate-to-severe ulcerative colitis.

21 Feb 2013

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

ADCs are used for a new type of targeted therapy that consists of a specific anti-cancer antibody or antibody fragment linked to a potent anti-cancer therapeutic.

20 Feb 2013

Ipsen, Inspiration Biopharmaceuticals sell IB1001 hemophilia B product to Cangene

Inspiration Biopharmaceuticals and Ipsen today announced the closing of the sale of the proprietary hemophilia B product, IB1001 (recombinant FIX), to Cangene Corporation.

20 Feb 2013

European Congress on Osteoporosis & Osteoarthritis to be held in Rome, Italy

The International Osteoporosis Foundation (IOF) and ESCEO have announced that a record number of abstracts (850+) have been submitted to the European Congress on Osteoporosis & Osteoarthritis (ESCEO13-IOF) and the 3rd IOF-ESCEO Pre-Clinical Symposium.

20 Feb 2013

Tiny microscope can help scientists observe neuronal firings in the brain

If you want to read a mouse's mind, it takes some fluorescent protein and a tiny microscope implanted in the rodent's head.

20 Feb 2013

Data from Eleven Biotherapeutics' EBI-005 preclinical study on ocular diseases

Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics, has published preclinical data in Proceedings of the National Academy of Sciences (PNAS) showing beneficial effects of EBI-005, the first rationally-designed topically administered IL-1 protein for the treatment of ocular diseases.

19 Feb 2013

BioCryst fourth quarter revenues decrease to $4.1 million

BioCryst Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year ended December 31, 2012.

19 Feb 2013

MILabs VECTor/CT installed by Molecular Imaging Center Antwerp (MICA) in Belgium

MILabs B.V. is pleased to announce that the Molecular Imaging Center Antwerp (MICA) in Belgium has installed a MILabs VECTor/CT to enhance their portfolio of pre-clinical nuclear oncology and neurology imaging and research capabilities.

18 Feb 2013

Allografts better survive implantation into brains of immunocompetent research mice

Researchers at the Johns Hopkins University in Baltimore, Md., and the Mossakowski Medical Research Centre in Warsaw, Poland, have found that nonself-donated cells (allografts) better survive implantation into the brains of immunocompetent research mice when the grafts are injected into the striatum (STR) of the brain rather than injected into the forceps minor (FM) region.

14 Feb 2013

Stress and mental illness: an interview with Professor Akira Sawa

As a psychiatrist I am interested in how stress may play a role in the pathology of adult mental disorders. You may know that most of the major mental illnesses, such as schizophrenia, mood-disorder, substance abuse or even anxiety disorder, become prominent in early adulthood.

14 Feb 2013

Preclinical News and Research

Surefire Medical’s latest line of infusion system and specialty catheters receive CE Mark approval

Sius single-use tangential flow filtration skid from Novasep

Recombinant Newcastle disease virus kills all kinds of prostate cancer cells

Adynxx initiates AYX1 Phase 2 study to prevent post-surgical pain

Okairos to commence novel RSV vaccine Phase I clinical trial

Orphan, CU to develop enzyme replacement therapy for CBS-deficient homocystinuria

Researchers determine that neuroblastoma is sensitive to BET bromodomain inhibitors

New mouse model can advance research on iPS cells to next step

Two new non-invasive technologies can improve early identification of tumor response to therapy

GCP could help lengthen life expectancy of certain prostate cancer patients

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

Ipsen, Inspiration Biopharmaceuticals sell IB1001 hemophilia B product to Cangene

European Congress on Osteoporosis & Osteoarthritis to be held in Rome, Italy

Tiny microscope can help scientists observe neuronal firings in the brain

Data from Eleven Biotherapeutics' EBI-005 preclinical study on ocular diseases

BioCryst fourth quarter revenues decrease to $4.1 million

MILabs VECTor/CT installed by Molecular Imaging Center Antwerp (MICA) in Belgium

Allografts better survive implantation into brains of immunocompetent research mice

Stress and mental illness: an interview with Professor Akira Sawa

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics